Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17307755 | 0.90 | BACE2 (0.40) | BACE1BACE2ALDH1A1HIF1A | |
| SCHEMBL17307748 | 0.90 | BACE2 (0.40) | BACE1BACE2ALDH1A1HIF1A | |
| SCHEMBL17307754 | 0.90 | BACE2 (0.40) | BACE1BACE2ALDH1A1HIF1A | |
| SCHEMBL17307822 | 0.89 | BACE1 (0.38) | BACE1BACE2ALDH1A1HIF1AL3MBTL1 | |
| SCHEMBL17307823 | 0.89 | BACE1 (0.38) | BACE1BACE2ALDH1A1HIF1AL3MBTL1 | |
| SCHEMBL17826421 | 0.85 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL17307825 | 0.83 | BACE1 (0.41) | BACE1BACE2 | |
| SCHEMBL17309155 | 0.80 | BACE1 (0.34) | BACE1BACE2ALDH1A1L3MBTL1HTT | |
| SCHEMBL15431699 | 0.80 | BACE2 (0.39) | BACE1BACE2 | |
| SCHEMBL15431693 | 0.80 | BACE2 (0.39) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365589-B2 | C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150344500-A1 | C2,C6 OXACYCLIC-FUSED THIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344500-A1 | C2,C6 OXACYCLIC-FUSED THIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885ALDH1A1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.